Orca-T, an investigational allogeneic T-cell immunotherapy, led to better quality-of-life outcomes and lower healthcare resource use than standard treatment with conventional allograft with tacrolimus/methotrexate (Tac/MTX), according to the phase 3 Precision-T study of patients with blood cancers receiving myeloablative transplants from matched donors.